ABIVAX Société Anonyme (ABVX)
- Previous Close
6.85 - Open
6.98 - Bid 6.55 x 100
- Ask 6.83 x 100
- Day's Range
6.66 - 6.98 - 52 Week Range
4.77 - 14.72 - Volume
17,148 - Avg. Volume
193,647 - Market Cap (intraday)
448.101M - Beta (5Y Monthly) 1.58
- PE Ratio (TTM)
-- - EPS (TTM)
-3.17 - Earnings Date Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.14
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
www.abivax.comRecent News: ABVX
View More
Performance Overview: ABVX
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABVX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABVX
View MoreValuation Measures
Market Cap
439.07M
Enterprise Value
386.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.62%
Return on Equity (ttm)
-148.98%
Revenue (ttm)
10.79M
Net Income Avi to Common (ttm)
-176.24M
Diluted EPS (ttm)
-3.17
Balance Sheet and Cash Flow
Total Cash (mrq)
144.36M
Total Debt/Equity (mrq)
269.12%
Levered Free Cash Flow (ttm)
-102.37M